Loading organizations...
Loading organizations...
Guiding cardiac therapeutics - all from your phone
Key people at SafeBeat.
SafeBeat was founded in 2020 by Rachita Navara (Founder) and Kunj Patel (Founder).
38 million people suffer from heart rhythm disorders and are recommended to start medications that can save their lives, but require rigorous ECG monitoring to start and remain on these pills. SafeBeat Rx moves beyond diagnostics to guide these therapeutics, powered by our ML ECG software that integrates with existing FDA-cleared wearables to allow seamless physician approval of drug dosing, all from a mobile phone.
We are a team of physicians, engineers, data scientists, and machine learning experts dedicated to using engineering to improve heart health.
Key people at SafeBeat.
SafeBeat was founded in 2020 by Rachita Navara (Founder) and Kunj Patel (Founder).
SafeBeat Rx is a digital health company that develops an AI-powered mobile platform to guide cardiac therapeutics remotely, primarily focusing on heart rhythm disorders such as atrial fibrillation. Their technology integrates with FDA-cleared wearable ECG and implantable cardiac monitors to provide clinicians with actionable insights and personalized treatment recommendations, enabling seamless remote patient monitoring and drug dosing management—all accessible via a smartphone. This approach addresses the challenge of rigorous ECG monitoring required for patients on life-saving cardiac medications, improving access and efficiency in cardiac care. SafeBeat Rx serves cardiologists, electrophysiologists, and healthcare providers managing heart rhythm disorders, positioning itself at the intersection of AI, digital therapeutics, and remote patient monitoring in cardiology[1][2][3][4].
Founded in 2020, SafeBeat Rx was co-founded by Dr. Rachita Navara, an electrophysiologist and bioengineer with a strong background in heart rhythm research, and Dr. Kunj Patel, a Harvard-trained interventional pain physician and applied mathematician. The idea emerged from Dr. Navara’s clinical experience, recognizing the need to expand access to cardiac drug therapies that require close ECG monitoring. Together, they assembled a multidisciplinary team of physicians, data scientists, AI engineers, and regulatory experts to build a solution that goes beyond diagnostics to actively guide therapeutics remotely. Early traction includes participation in Y Combinator’s Summer 2021 batch and successful use cases such as remote management of atrial fibrillation patients starting antiarrhythmic drugs[2][4][6].
SafeBeat Rx rides the growing trend of digital health and remote patient monitoring accelerated by the COVID-19 pandemic and the increasing prevalence of cardiovascular diseases globally. The timing is critical as healthcare systems seek scalable, cost-effective solutions to manage chronic conditions like heart rhythm disorders outside hospital settings. Market forces such as rising demand for telehealth, advances in wearable technology, and regulatory support for AI in healthcare favor SafeBeat’s model. By enabling remote therapeutic guidance, SafeBeat influences the broader ecosystem by pushing digital health beyond passive monitoring toward active, AI-enabled treatment management, potentially reducing hospital readmissions and improving patient outcomes[1][2][5].
Looking ahead, SafeBeat Rx is poised to expand its platform capabilities, potentially incorporating broader cardiac conditions like heart failure and integrating additional biometric data streams. Trends such as increased adoption of AI in clinical decision support, reimbursement for remote therapeutic monitoring, and patient demand for convenient care will shape their growth trajectory. As the company moves from prototype to commercial product, its influence could extend across cardiology and digital therapeutics, setting new standards for remote cardiac care. SafeBeat’s mission to guide cardiac therapeutics entirely from a phone encapsulates a future where personalized, AI-driven care is accessible anytime, anywhere, transforming heart health management at scale[2][4][5].
